Ironwood Pharmaceuticals Company Insiders
IRWD Stock | USD 3.34 0.18 5.11% |
About 72% of Ironwood Pharmaceuticals' corporate insiders are selling. The analysis of the overall insider sentiment regarding Ironwood Pharmaceuticals suggests that many insiders are alarmed. Ironwood Pharmaceuticals employs about 267 people. The company is managed by 16 executives with a total tenure of roughly 20 years, averaging almost 1.0 years of service per executive, having 16.69 employees per reported executive.
Julie McHugh Director Independent Director |
Thomas McCourt SVP Chief Commercial Officer and Sr. VP of Marketing and Sales |
Ironwood Pharmaceuticals' Insider Buying Vs Selling
28
Selling | Buying |
Latest Trades
2024-11-18 | Sravan Kumar Emany | Disposed 11001 @ 4.08 | View | ||
2024-08-12 | Minardo John | Disposed 9910 @ 4.27 | View | ||
2024-06-10 | Julie Mchugh | Disposed 22766 @ 6.29 | View | ||
2024-06-06 | Catherine Moukheibir | Disposed 44426 @ 6.36 | View | ||
2024-03-06 | Jon R Duane | Acquired 6920 @ 8.7 | View | ||
2024-03-04 | Sravan Kumar Emany | Acquired 10684 @ 9.38 | View | ||
2024-02-12 | Thomas A Mccourt | Disposed 177164 @ 15.24 | View |
Monitoring Ironwood Pharmaceuticals' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Ironwood |
Ironwood Pharmaceuticals' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Ironwood Pharmaceuticals' future performance. Based on our forecasts, it is anticipated that Ironwood will maintain a workforce of about 270 employees by December 2024.Ironwood Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of 0.1305 % which means that it generated a profit of $0.1305 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.7472) %, meaning that it created substantial loss on money invested by shareholders. Ironwood Pharmaceuticals' management efficiency ratios could be used to measure how well Ironwood Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At present, Ironwood Pharmaceuticals' Return On Equity is projected to slightly grow based on the last few years of reporting. At present, Ironwood Pharmaceuticals' Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 356.5 M, whereas Non Currrent Assets Other are forecasted to decline to about 3.4 M.The current year's Net Income Applicable To Common Shares is expected to grow to about 211.4 M, whereas Common Stock Shares Outstanding is forecasted to decline to about 137.1 M.
Ironwood Pharmaceuticals Workforce Comparison
Ironwood Pharmaceuticals is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 8,924. Ironwood Pharmaceuticals holds roughly 267 in number of employees claiming about 2.99% of equities under Health Care industry.
Ironwood Pharmaceuticals Profit Margins
The company has Profit Margin (PM) of (0.01) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.28 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.28.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.74 | 0.9964 |
|
|
Ironwood Pharmaceuticals Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ironwood Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ironwood Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Ironwood Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-09-01 | 0.5 | 1 | 2 | 3,282 | 13,017 |
2024-06-01 | 1.125 | 9 | 8 | 197,060 | 244,921 |
2024-03-01 | 2.0909 | 23 | 11 | 1,537,806 | 584,474 |
2023-12-01 | 0.6667 | 2 | 3 | 2,919 | 19,874 |
2023-09-01 | 2.0 | 4 | 2 | 47,968 | 9,021 |
2023-06-01 | 2.0 | 10 | 5 | 181,745 | 100,409 |
2023-03-01 | 0.8261 | 19 | 23 | 1,064,751 | 543,747 |
2022-12-01 | 0.2 | 1 | 5 | 1,244 | 56,494 |
2022-09-01 | 0.1818 | 2 | 11 | 19,415 | 213,572 |
2022-06-01 | 0.8571 | 12 | 14 | 386,966 | 659,266 |
2022-03-01 | 0.6316 | 12 | 19 | 665,261 | 120,262 |
2021-12-01 | 0.4444 | 4 | 9 | 89,183 | 168,402 |
2021-09-01 | 1.25 | 5 | 4 | 103,820 | 10,910 |
2021-06-01 | 3.75 | 15 | 4 | 339,097 | 27,880 |
2021-03-01 | 1.1579 | 22 | 19 | 2,991,090 | 88,845 |
2020-12-01 | 0.6 | 9 | 15 | 183,946 | 227,633 |
2020-09-01 | 0.3333 | 1 | 3 | 1,600 | 9,214 |
2020-06-01 | 0.4074 | 11 | 27 | 219,059 | 375,059 |
2020-03-01 | 0.3462 | 9 | 26 | 576,527 | 341,666 |
2019-12-01 | 0.8333 | 5 | 6 | 207,020 | 4,834 |
2019-09-01 | 0.3571 | 5 | 14 | 249,192 | 499,497 |
2019-06-01 | 1.375 | 44 | 32 | 1,102,981 | 3,486,670 |
2019-03-01 | 0.4595 | 17 | 37 | 3,047,252 | 3,020,904 |
2018-12-01 | 0.7727 | 17 | 22 | 6,090,398 | 6,368,689 |
2018-09-01 | 0.8947 | 17 | 19 | 306,489 | 536,123 |
2018-06-01 | 5.0 | 10 | 2 | 130,045 | 3,500 |
2018-03-01 | 1.0769 | 14 | 13 | 1,619,537 | 139,812 |
2017-12-01 | 0.4 | 4 | 10 | 140,159 | 259,269 |
2017-09-01 | 0.3333 | 1 | 3 | 153.00 | 3,707 |
2017-06-01 | 2.2 | 11 | 5 | 190,142 | 133,200 |
2017-03-01 | 0.9 | 18 | 20 | 1,752,199 | 434,978 |
2016-12-01 | 1.0 | 5 | 5 | 324,822 | 333,700 |
2016-09-01 | 1.0 | 2 | 2 | 332.00 | 3,407 |
2016-06-01 | 2.6 | 13 | 5 | 208,234 | 32,475 |
2016-03-01 | 1.0 | 17 | 17 | 1,990,478 | 955,505 |
2015-12-01 | 1.0 | 6 | 6 | 348,569 | 423,733 |
2015-09-01 | 4.0 | 4 | 1 | 7,934 | 3,725 |
2015-03-01 | 0.8519 | 23 | 27 | 1,451,490 | 2,853,856 |
2014-12-01 | 0.6429 | 9 | 14 | 156,803 | 322,164 |
2014-09-01 | 4.5 | 9 | 2 | 2,225,705 | 65,407 |
2014-06-01 | 1.3846 | 18 | 13 | 259,192 | 896,914 |
2014-03-01 | 0.7333 | 22 | 30 | 926,411 | 3,327,497 |
2013-12-01 | 1.8571 | 13 | 7 | 3,701,748 | 601,080 |
2013-09-01 | 5.5 | 11 | 2 | 104,727 | 950,000 |
2013-06-01 | 2.8 | 14 | 5 | 263,976 | 382,434 |
2013-03-01 | 1.3889 | 25 | 18 | 1,256,501 | 5,061,731 |
2012-12-01 | 1.1053 | 21 | 19 | 180,196 | 450,566 |
2012-09-01 | 0.2903 | 9 | 31 | 3,978 | 942,455 |
2012-06-01 | 2.0 | 8 | 4 | 165,911 | 156,874 |
2012-03-01 | 2.0 | 10 | 5 | 596,956 | 1,343,656 |
2011-12-01 | 3.0 | 12 | 4 | 84,233 | 197,174 |
2011-09-01 | 5.0 | 10 | 2 | 69,797 | 66,666 |
2011-06-01 | 1.1111 | 10 | 9 | 61,674 | 644,400 |
2011-03-01 | 0.9286 | 13 | 14 | 181,953 | 165,621 |
2010-03-01 | 0.1579 | 3 | 19 | 20,366 | 10,617,262 |
Ironwood Pharmaceuticals Notable Stakeholders
An Ironwood Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Ironwood Pharmaceuticals often face trade-offs trying to please all of them. Ironwood Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Ironwood Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Thomas McCourt | Chief Commercial Officer and Sr. VP of Marketing and Sales | Profile | |
Julie McHugh | Independent Director | Profile | |
Matt Roache | Director Relations | Profile | |
MPH MD | VP Development | Profile | |
MBA MS | VP Operations | Profile | |
Jana Noeldeke | Basel Leader | Profile | |
Ronald Silver | Corporate Officer | Profile | |
Marcel Moulaison | Vice Operations | Profile | |
Beth Calitri | Head Relations | Profile | |
Sravan Emany | Principal VP | Profile | |
Jason Rickard | VP COO | Profile | |
Mike Nanfito | Vice Excellence | Profile | |
John Minardo | Chief VP | Profile | |
Michael MD | Senior Officer | Profile | |
Greg Martini | Vice Relations | Profile | |
Andrew Davis | Senior Officer | Profile |
About Ironwood Pharmaceuticals Management Performance
The success or failure of an entity such as Ironwood Pharmaceuticals often depends on how effective the management is. Ironwood Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Ironwood management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Ironwood management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (2.14) | (2.04) | |
Return On Capital Employed | 1.07 | 1.13 | |
Return On Assets | (2.13) | (2.02) | |
Return On Equity | 2.89 | 3.04 |
Please note, the presentation of Ironwood Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Ironwood Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Ironwood Pharmaceuticals' management manipulating its earnings.
Ironwood Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Ironwood Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Ironwood Pharmaceuticals within its industry.Ironwood Pharmaceuticals Manpower Efficiency
Return on Ironwood Pharmaceuticals Manpower
Revenue Per Employee | 1.7M | |
Revenue Per Executive | 27.7M | |
Net Loss Per Employee | 3.8M | |
Net Loss Per Executive | 62.6M |
Complementary Tools for Ironwood Stock analysis
When running Ironwood Pharmaceuticals' price analysis, check to measure Ironwood Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ironwood Pharmaceuticals is operating at the current time. Most of Ironwood Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ironwood Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ironwood Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ironwood Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
CEOs Directory Screen CEOs from public companies around the world | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Fundamental Analysis View fundamental data based on most recent published financial statements |